Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program.
Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system.
http://www.dailystockdeals.com/topten/hot-biotechnology-stocks-idra-04-01-2013
Source: company, OxBridge Research, Daily Stock Deals
CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Idera Pharmaceuticals, Inc. (IDRA) today announced that it has completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that its protocol for a Phase 2 study of IMO-8400 in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9, and is in clinical development for the treatment of autoimmune diseases.
During the first quarter of 2013, the Company completed the escalating single-dose portion of the Phase 1 trial of IMO-8400 and has now completed patient dosing in the multiple-dose portion of the trial. The multiple-dose portion of the trial involved two dose levels of IMO-8400, 0.3 and 0.6 mg/kg, and placebo, with six subjects receiving each treatment of four weekly doses. The Company expects to report top-line data from the multiple-dose portion of the trial later in the second quarter of 2013.
Source: company, OxBridge Research, Daily Stock Deals
HEB, Hemispherx Biopharma
Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, an experimental drug under clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, an experimental low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases.
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
Source: company, OxBridge Research, Daily Stock Deals